Orchid Pharma has announced that a meeting of its Board of Directors will be held on February 11, 2026, to consider and approve the unaudited limited reviewed financial results for the Quarter-III of the financial year 2025-26, which ended on December 31, 2025. The company also stated that the trading window, which closed on January 01, 2026, will remain closed until 48 hours after the declaration of the unaudited results.
Board Meeting for Financial Results
Orchid Pharma has scheduled a meeting of its Board of Directors to be held on February 11, 2026. The primary purpose of the meeting is to review and approve the Unaudited Limited Reviewed Financial Results for the third quarter (Q3: Oct-Dec) of the financial year 2025-26.
Trading Window Closure
The company also announced that the trading window for dealing in the company’s securities has been closed since January 01, 2026. This closure will remain in effect until 48 hours after the announcement of the unaudited financial results for the quarter ended December 31, 2025. This measure ensures compliance and prevents insider trading during the sensitive period leading up to the financial results announcement.
Source: BSE
